Alan Cyril Mullen, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatic Stellate Cells | 4 | 2022 | 117 | 1.920 |
Why?
|
| Liver Cirrhosis | 5 | 2025 | 1960 | 1.070 |
Why?
|
| Smad3 Protein | 3 | 2016 | 166 | 1.050 |
Why?
|
| Transforming Growth Factor beta | 6 | 2021 | 1996 | 1.010 |
Why?
|
| Embryonic Stem Cells | 5 | 2017 | 1250 | 0.800 |
Why?
|
| Endoderm | 2 | 2020 | 165 | 0.790 |
Why?
|
| Cell Differentiation | 14 | 2021 | 11669 | 0.770 |
Why?
|
| Fatty Liver | 2 | 2024 | 809 | 0.710 |
Why?
|
| Phase Transition | 1 | 2020 | 70 | 0.700 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2025 | 2521 | 0.620 |
Why?
|
| Hepatocytes | 1 | 2025 | 1247 | 0.580 |
Why?
|
| Goosecoid Protein | 1 | 2016 | 9 | 0.560 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2022 | 832 | 0.530 |
Why?
|
| Cicatrix | 1 | 2022 | 798 | 0.520 |
Why?
|
| Ceramides | 1 | 2017 | 203 | 0.510 |
Why?
|
| Adenosine | 2 | 2017 | 820 | 0.500 |
Why?
|
| Adult Stem Cells | 1 | 2017 | 221 | 0.490 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2017 | 430 | 0.480 |
Why?
|
| Transcription Factors | 8 | 2023 | 12168 | 0.460 |
Why?
|
| Smad2 Protein | 1 | 2014 | 144 | 0.440 |
Why?
|
| Single-Cell Analysis | 1 | 2025 | 2540 | 0.420 |
Why?
|
| Collagen | 2 | 2022 | 2643 | 0.420 |
Why?
|
| Liver | 3 | 2025 | 7577 | 0.410 |
Why?
|
| Interleukin-12 | 3 | 2024 | 577 | 0.390 |
Why?
|
| Histones | 2 | 2020 | 2601 | 0.360 |
Why?
|
| Th1 Cells | 3 | 2002 | 1042 | 0.300 |
Why?
|
| Gene Expression Regulation | 8 | 2017 | 11928 | 0.300 |
Why?
|
| Genome, Human | 2 | 2020 | 4446 | 0.300 |
Why?
|
| Interferon-gamma | 5 | 2024 | 3160 | 0.290 |
Why?
|
| RNA | 1 | 2017 | 2720 | 0.290 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 1752 | 0.280 |
Why?
|
| Pluripotent Stem Cells | 1 | 2014 | 809 | 0.270 |
Why?
|
| Signal Transduction | 10 | 2024 | 23645 | 0.260 |
Why?
|
| Trans-Activators | 4 | 2002 | 2857 | 0.250 |
Why?
|
| Myofibroblasts | 2 | 2017 | 230 | 0.240 |
Why?
|
| End Stage Liver Disease | 2 | 2019 | 370 | 0.230 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 5 | 2003 | 977 | 0.230 |
Why?
|
| Glucokinase | 1 | 2023 | 99 | 0.220 |
Why?
|
| T-Box Domain Proteins | 5 | 2005 | 472 | 0.220 |
Why?
|
| Methyltransferases | 2 | 2017 | 373 | 0.210 |
Why?
|
| Ethers | 1 | 2022 | 73 | 0.200 |
Why?
|
| Spiro Compounds | 1 | 2022 | 69 | 0.200 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2022 | 120 | 0.200 |
Why?
|
| Gene Expression Profiling | 3 | 2025 | 9538 | 0.190 |
Why?
|
| Acid Ceramidase | 1 | 2020 | 21 | 0.180 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2022 | 478 | 0.180 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2023 | 638 | 0.170 |
Why?
|
| Myoblasts | 1 | 2021 | 234 | 0.170 |
Why?
|
| Macrophages | 2 | 2025 | 5799 | 0.160 |
Why?
|
| Homeodomain Proteins | 2 | 2014 | 2429 | 0.160 |
Why?
|
| Gene Expression Regulation, Developmental | 4 | 2017 | 3610 | 0.160 |
Why?
|
| Fibrosis | 2 | 2022 | 2080 | 0.150 |
Why?
|
| Acetylation | 1 | 2020 | 1056 | 0.150 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2021 | 553 | 0.140 |
Why?
|
| Exoribonucleases | 1 | 2017 | 88 | 0.140 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2016 | 1367 | 0.140 |
Why?
|
| Sequence Analysis, RNA | 1 | 2025 | 2040 | 0.140 |
Why?
|
| Gastrulation | 1 | 2016 | 37 | 0.140 |
Why?
|
| Half-Life | 1 | 2017 | 651 | 0.130 |
Why?
|
| Lysine | 1 | 2020 | 1000 | 0.130 |
Why?
|
| Transcription Initiation Site | 1 | 2016 | 190 | 0.130 |
Why?
|
| RNA Stability | 1 | 2017 | 319 | 0.120 |
Why?
|
| RNA, Messenger | 5 | 2017 | 12800 | 0.120 |
Why?
|
| Methylation | 1 | 2017 | 1078 | 0.120 |
Why?
|
| Attitude | 1 | 2019 | 771 | 0.110 |
Why?
|
| Mice | 16 | 2024 | 82029 | 0.110 |
Why?
|
| Palliative Care | 2 | 2019 | 3643 | 0.110 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2016 | 3671 | 0.110 |
Why?
|
| DNA Transposable Elements | 1 | 2017 | 764 | 0.110 |
Why?
|
| Mice, Knockout | 5 | 2024 | 14488 | 0.110 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 858 | 0.110 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2020 | 1966 | 0.100 |
Why?
|
| Receptors, Interleukin-12 | 2 | 2002 | 26 | 0.100 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2017 | 845 | 0.100 |
Why?
|
| Humans | 22 | 2025 | 768166 | 0.100 |
Why?
|
| Advance Care Planning | 1 | 2019 | 698 | 0.090 |
Why?
|
| Exons | 1 | 2017 | 2394 | 0.090 |
Why?
|
| HeLa Cells | 1 | 2017 | 3074 | 0.090 |
Why?
|
| MyoD Protein | 1 | 2011 | 143 | 0.090 |
Why?
|
| High-Throughput Screening Assays | 1 | 2017 | 942 | 0.090 |
Why?
|
| Organ Specificity | 1 | 2016 | 1968 | 0.090 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2011 | 221 | 0.090 |
Why?
|
| Receptors, Interleukin | 2 | 2002 | 243 | 0.090 |
Why?
|
| Epigenomics | 1 | 2016 | 960 | 0.090 |
Why?
|
| Insulin Resistance | 1 | 2024 | 3986 | 0.090 |
Why?
|
| DNA-Binding Proteins | 3 | 2002 | 9615 | 0.090 |
Why?
|
| Base Sequence | 3 | 2017 | 12421 | 0.090 |
Why?
|
| Gene Expression | 2 | 2002 | 7598 | 0.090 |
Why?
|
| RNA, Untranslated | 1 | 2013 | 455 | 0.080 |
Why?
|
| Animals | 17 | 2024 | 169246 | 0.080 |
Why?
|
| Extracellular Matrix | 1 | 2017 | 1738 | 0.080 |
Why?
|
| Drug Discovery | 1 | 2017 | 1068 | 0.080 |
Why?
|
| Cluster Analysis | 1 | 2016 | 2732 | 0.080 |
Why?
|
| Adenine | 1 | 2014 | 995 | 0.080 |
Why?
|
| Cell Lineage | 5 | 2014 | 2575 | 0.080 |
Why?
|
| RNA-Binding Proteins | 1 | 2017 | 1890 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 6 | 2003 | 6231 | 0.080 |
Why?
|
| Antigens, Differentiation | 2 | 2001 | 921 | 0.070 |
Why?
|
| Liver Transplantation | 1 | 2019 | 2401 | 0.070 |
Why?
|
| Disease Progression | 1 | 2023 | 13671 | 0.070 |
Why?
|
| RNA Processing, Post-Transcriptional | 2 | 2022 | 393 | 0.070 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 3269 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 9 | 2024 | 22379 | 0.060 |
Why?
|
| Computational Biology | 1 | 2017 | 3568 | 0.060 |
Why?
|
| Transcription, Genetic | 2 | 2013 | 7608 | 0.060 |
Why?
|
| HIV-1 | 1 | 2022 | 6961 | 0.060 |
Why?
|
| GATA3 Transcription Factor | 2 | 2002 | 163 | 0.060 |
Why?
|
| Genome-Wide Association Study | 1 | 2023 | 12795 | 0.060 |
Why?
|
| Receptors, Interferon | 1 | 2024 | 115 | 0.060 |
Why?
|
| Lymphocyte Activation | 4 | 2003 | 5505 | 0.060 |
Why?
|
| Immunoconjugates | 2 | 2001 | 975 | 0.050 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 3833 | 0.050 |
Why?
|
| Th2 Cells | 3 | 2003 | 1078 | 0.050 |
Why?
|
| Terminal Repeat Sequences | 1 | 2022 | 70 | 0.050 |
Why?
|
| Obesity | 1 | 2024 | 13090 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2023 | 2909 | 0.050 |
Why?
|
| RNA, Antisense | 1 | 2022 | 136 | 0.050 |
Why?
|
| STAT4 Transcription Factor | 1 | 2001 | 94 | 0.050 |
Why?
|
| Nucleosides | 1 | 2022 | 130 | 0.050 |
Why?
|
| CREB-Binding Protein | 1 | 2001 | 147 | 0.050 |
Why?
|
| Interleukin-4 | 2 | 2002 | 1156 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2005 | 4648 | 0.050 |
Why?
|
| Immunologic Memory | 2 | 2005 | 1377 | 0.040 |
Why?
|
| Cell Fusion | 1 | 2021 | 294 | 0.040 |
Why?
|
| Myofibrils | 1 | 2021 | 143 | 0.040 |
Why?
|
| Models, Immunological | 1 | 2001 | 518 | 0.040 |
Why?
|
| Chickens | 1 | 2021 | 845 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2022 | 996 | 0.040 |
Why?
|
| Cell Division | 2 | 2001 | 4473 | 0.030 |
Why?
|
| Cell Line | 3 | 2014 | 15597 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2021 | 1903 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2002 | 1750 | 0.030 |
Why?
|
| Cell Cycle | 2 | 2001 | 2932 | 0.030 |
Why?
|
| Cells, Cultured | 3 | 2016 | 19015 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2002 | 1505 | 0.030 |
Why?
|
| Cultural Competency | 1 | 2019 | 303 | 0.030 |
Why?
|
| Polyadenylation | 1 | 2016 | 114 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2003 | 1815 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2019 | 779 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2016 | 515 | 0.030 |
Why?
|
| Cell Communication | 1 | 2021 | 1660 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2002 | 3740 | 0.030 |
Why?
|
| Chromatin | 2 | 2002 | 2981 | 0.030 |
Why?
|
| Male | 4 | 2025 | 364719 | 0.030 |
Why?
|
| Glucose | 1 | 2023 | 4352 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2016 | 1715 | 0.020 |
Why?
|
| Conserved Sequence | 1 | 2014 | 1162 | 0.020 |
Why?
|
| DNA Methylation | 2 | 2002 | 4428 | 0.020 |
Why?
|
| Female | 4 | 2025 | 397192 | 0.020 |
Why?
|
| Molecular Sequence Data | 3 | 2014 | 17622 | 0.020 |
Why?
|
| Adult | 1 | 2025 | 223646 | 0.020 |
Why?
|
| Alleles | 1 | 2001 | 6894 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2014 | 2627 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2001 | 3409 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2001 | 4206 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2019 | 26379 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2021 | 11095 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2001 | 5804 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2019 | 3620 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 3428 | 0.020 |
Why?
|
| Mice, Transgenic | 3 | 2005 | 9561 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 3929 | 0.010 |
Why?
|
| Interleukin-15 | 1 | 2005 | 186 | 0.010 |
Why?
|
| Communication | 1 | 2019 | 3905 | 0.010 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2005 | 564 | 0.010 |
Why?
|
| Arenaviridae Infections | 1 | 2003 | 53 | 0.010 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 2003 | 130 | 0.010 |
Why?
|
| Perforin | 1 | 2003 | 167 | 0.010 |
Why?
|
| Stem Cells | 1 | 2016 | 3537 | 0.010 |
Why?
|
| Lymphocytic choriomeningitis virus | 1 | 2003 | 176 | 0.010 |
Why?
|
| Granzymes | 1 | 2003 | 277 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2002 | 1142 | 0.010 |
Why?
|
| United States | 2 | 2019 | 73039 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 2003 | 13421 | 0.010 |
Why?
|
| Antigens, CD | 2 | 2001 | 4035 | 0.010 |
Why?
|
| Leishmania major | 1 | 2000 | 60 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2003 | 1353 | 0.010 |
Why?
|
| Genes, Lethal | 1 | 2000 | 224 | 0.010 |
Why?
|
| Splenomegaly | 1 | 2000 | 192 | 0.010 |
Why?
|
| Crosses, Genetic | 1 | 2000 | 752 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2014 | 10474 | 0.010 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2000 | 137 | 0.010 |
Why?
|
| Lymphatic Diseases | 1 | 2000 | 319 | 0.010 |
Why?
|
| Serine Endopeptidases | 1 | 2003 | 1027 | 0.010 |
Why?
|
| CpG Islands | 1 | 2002 | 1208 | 0.010 |
Why?
|
| Time Factors | 1 | 2019 | 40218 | 0.010 |
Why?
|
| Transgenes | 1 | 2000 | 1016 | 0.010 |
Why?
|
| Cell Death | 1 | 2001 | 1679 | 0.010 |
Why?
|
| Cytokines | 2 | 2003 | 7453 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2000 | 1864 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2002 | 2675 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 3711 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2002 | 5902 | 0.010 |
Why?
|
| Mutation | 1 | 2014 | 30238 | 0.010 |
Why?
|
| Homeostasis | 1 | 2000 | 3348 | 0.000 |
Why?
|
| Phenotype | 1 | 2005 | 16726 | 0.000 |
Why?
|
| T-Lymphocytes | 1 | 2000 | 10266 | 0.000 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2000 | 18065 | 0.000 |
Why?
|